1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Hunting down the cause of ME/CFS & other challenging disorders - Lipkin in London
In a talk to patients in London on 3rd September, Dr. W. Ian Lipkin described the extraordinary lengths he and his team are prepared to go to in order to track down the source of an illness, with examples ranging from autism to the strange case of Kawasaki disease.
Discuss the article on the Forums.

Rituximab maintenance therapy: a step forward in follicular lymphoma

Discussion in 'Rituximab: News and Research' started by Andrew, Feb 4, 2012.

  1. Andrew

    Andrew Senior Member

    Messages:
    1,981
    Likes:
    1,275
    Los Angeles, USA
  2. Snow Leopard

    Snow Leopard Senior Member

    Messages:
    2,419
    Likes:
    2,095
    Australia
    Thanks.

    Which study has followed this up for the longest period of time? This one appears to be about 2 years (and n=151).
     
  3. Andrew

    Andrew Senior Member

    Messages:
    1,981
    Likes:
    1,275
    Los Angeles, USA
    I don't know what the follow up was. I thought I'd get this posted and maybe check later.
     
  4. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    7,420
    Likes:
    4,820
    australia (brisbane)
    I wonder if maintenance can be maintain with antivirals after ritux treatment. AV's have a saver side effect profile from what we know so far??

    cheers!!!
     
  5. Andrew

    Andrew Senior Member

    Messages:
    1,981
    Likes:
    1,275
    Los Angeles, USA
    I guess it depends on how cfs works. If killing b cells is the trick, then I don't see what the AV would do.
     
  6. anciendaze

    anciendaze Senior Member

    Messages:
    909
    Likes:
    1,073
    This depends on why killing CD20 B-cells works. These are cells which hold antigens as memory cells for the immune system. In the case of viruses the entire virus may be in there. Holding the virus in check while other B-cells reconstitute normal immune function might be useful.
     
  7. currer

    currer Senior Member

    Messages:
    1,324
    Likes:
    774
    It is not known how this therapy works for other diseases - so to expect answers in the case of ME is a bit much. Many drugs are used therapeutically without knowing how they work exactly.

    They could be killing off the retrovirally infected cells and thus reducing the tissue load. Who knows?

    We need more research.
     
  8. Snow Leopard

    Snow Leopard Senior Member

    Messages:
    2,419
    Likes:
    2,095
    Australia
    From an idealistic point of view, if the phase 3 trial for Rituximab is successful, it is beneficial not necessarily just as a (non-specific) treatment, but also a clue for further research and development of more specific drugs. Responding to Rituximab creates a novel subgroup for study. (and blood can be banked beforehand for later study).

    Of course as Currer said, expecting answers in the short term is a bit much.
     

See more popular forum discussions.

Share This Page